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ABSTRACT
Ubiquitin-Specific Proteases (USPs) are deubiquitinating enzymes frequently 
deregulated in human malignancies. Here, we show that USP54 is overexpressed 
in intestinal stem cells and demonstrate that its downregulation in colorectal 
carcinoma cells impedes tumorigenesis. We have generated mutant mice deficient 
for this deubiquitinase, which are viable and fertile, and protected against chemically-
induced colorectal carcinoma. Furthermore, we show that USP54 is upregulated in 
human colon cancer and associates with poor prognosis. In agreement with these 
results, Usp54 downregulation in mouse melanoma cells inhibits lung metastasis 
formation. Collectively, this work has uncovered the pro-tumorigenic properties of 
USP54, highlighting the importance of deubiquitinating enzymes as promising targets 
for the development of specific anti-cancer therapies.
INTRODUCTION
Proteases have essential functions in the regulation 
and execution of most physiological processes and 
pathological conditions [1-3]. Consequently, alterations 
in their structure or regulation are associated with 
diverse pathologies, such as arthritis, neurodegenerative 
alterations, cardiovascular diseases and cancer. In 
this sense, proteases have raised remarkable interest 
as potential targets of anticancer therapies [4-6]. 
Nevertheless, the success of these strategies has been 
limited by the complexity of the entire protease repertoire, 
defined as degradome, and by the fact that not all proteases 
exhibit pro-tumorigenic roles in human malignancies, as 
the list of human proteases with tumor suppressive roles in 
cancer has been growing over the last decades [7].
Among all proteases whose function is involved 
in cancer regulation, deubiquitinases or DUBs are of 
particular interest due to their wide functional diversity 
[8, 9]. DUBs are critical regulators of ubiquitin-mediated 
signaling pathways because of their ability to cleave 
the isopeptide bond that links ubiquitin chains to target 
proteins. Based on structural and sequence similarities, 
DUBs are grouped into six families: ubiquitin-specific 
proteases (USPs), ubiquitin carboxy-terminal hydrolases 
(UCHs), ovarian-tumor proteases (OTUs), Machado-
Joseph disease protein domain proteases (MJDs) and 
monocyte chemotactic protein-induced proteins (MCPIPs), 
all of them cysteine proteases, and JAMM/MPN domain-
associated metallopeptidases, which is the only family 
that belongs to the catalytic class of metalloproteases 
[10]. With more than 50 members, USPs constitute the 
largest family of DUBs [11], and have a profound impact 
on the regulation of multiple biological processes that are 
frequently altered in cancer [10]. Previous studies have 
reported that USPs exhibit tumor suppressing or oncogenic 
functions due to mutations or changes in their expression 
levels. Furthermore, there are USPs with pro-tumorigenic 
and anti-tumorigenic activities depending on the cellular 
context or the target affected by their regulation [12, 
13]. In this regard, sequence alterations of USP54 have 
been recently described in human acute lymphoblastic 
leukemia [14]. However, the functional relevance of this 
deubiquitinating enzyme in solid tumors has not been 
explored so far. 
In this work, we have demonstrated that USP54 
is overexpressed in intestinal cancer stem cells (CSCs) 
and that its downregulation reduces the tumorigenicity 
of colon cancer cells both in vitro and in vivo. To further 
investigate the in vivo function of USP54 in cancer, we 
have generated mutant mice deficient for this DUB. These 
mice are viable and fertile with no obvious abnormalities. 
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We have found that USP54 deficiency protects against 
azoxymethane-induced colon carcinoma and inhibits 
metastasis formation by melanoma cells, indicating 
that this DUB functions as an oncogenic factor in both 
malignancies. Finally, we show that high levels of USP54 
are a poor prognosis marker in colorectal carcinoma, 
suggesting the interest of this enzyme as a potential target 
of anticancer therapies. 
RESULTS
USP54 is overexpressed in intestinal stem cells 
and promotes cancer progression
To explore the role of DUBs in cancer stem cell 
biology, we have analyzed the expression of several 
DUBs in publicly available transcriptional profiles of 
intestinal epithelial cells, which had been FACS-sorted 
according to high, medium or low EphB2 receptor 
levels to obtain intestinal stem cell (ISC)-enriched cell 
populations [15]. This analysis revealed that USP54 was 
overexpressed in cells with high expression of both Lgr5 
and EphB2 receptor, supporting that USP54 expression 
is upregulated in intestinal cells with stem properties 
(Figure 1A). We then validated these results in cells 
derived from primary tumors expanded as subcutaneous 
xenografts in immunodeficient mice and sorted in three 
populations displaying high, medium or low EphB2 
receptor expression. Similarly, USP54 was upregulated 
in the samples with high EphB2 receptor levels (Figure 
1B), suggesting a role of USP54 in maintaining the stem 
characteristics of both ISCs and CSCs. In agreement with 
these results, silencing of USP54 in HCT116 colorectal 
carcinoma cells with two different shRNAs (shUSP54.854 
and shUSP54.856), reduced their ability to grow in soft 
agar (Figure 1C). Downregulation of USP54 expression 
was verified by qRT-PCR (Figure 1D). Moreover, the 
proliferation rate of HCT116 cells was decreased upon 
USP54 depletion, compared to wild-type cells (Figure 
1E). Similarly, USP54 downregulation decreased the 
Figure 1: USP54 is upregulated in intestinal stem cells and induces colorectal carcinoma progression. A. Analysis of 
USP54 expression from microarray data (GEO accession number GSE27605). High, high Lgr5 or EphB2 receptor expression levels; Med, 
medium EphB2 receptor expression levels; Low, low Lgr5 or EphB2 receptor expression levels. B. qRT-PCR analysis of USP54 expression 
in two different colorectal carcinoma xenografts (SP5 and SP9), two-tailed Student’s t-test (***, P < 0.001). C. Anchorage-independent 
growth of control (pLKO.1) and USP54-depleted HCT116 cells (shUSP54.854 and shUSP54.856), two-tailed Student’s t-test (**, P < 0.01; 
***, P < 0.001). RFU, relative fluorescence units. D. qRT-PCR analysis of USP54 expression in HCT116 cells transduced with control 
(pLKO.1) or USP54-specific shRNAs (shUSP54.854 and shUSP54.856). Statistical significance was assessed by two-tailed Student’s t-test 
(***, P < 0.001). E. MTT proliferation analysis of wild-type and USP54-deficient HCT116 cells, Mann Whitney-Wilcoxon test (**, P < 
0.01). F. Average area of invasion of HCT116 cells transduced with empty vector (pLKO.1) or USP54-specific shRNAs (shUSP54.854 
and shUSP54.856). Mann Whitney-Wilcoxon test was used to analyze statistical significance (*, P < 0.05; **, P < 0.01). G. Tumor 
xenograft model performed with subcutaneously injected control and USP54-depleted HCT116 cells. Data are presented as mean ± SEM 
and statistical significance was assessed by using a non-parametric Mann Whitney-Wilcoxon test (*, P < 0.05). 
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invasiveness of HCT116 cells (Figure 1F). Consistent 
with these findings, depletion of USP54 decreased the 
tumorigenicity of HCT116 when injected into nude mice 
(Figure 1G). Altogether, these data support the role of 
USP54 in promoting colorectal carcinoma and suggest a 
new function of USP54 in controlling the stem properties 
of intestinal cells.
Usp54 is dispensable for embryonic development 
and normal growth of adult mice
To further evaluate the role of USP54 in cancer, 
we generated a mouse model deficient for this DUB by 
using a knockout-first (KF) strategy. Mice homozygous 
for the KF allele, hereafter referred as Usp54KF/KF, were 
viable and fertile without any obvious alteration. Thus, we 
did not find any difference in survival between Usp54+/+ 
and Usp54KF/KF mice, neither in males (Figure 2A) nor 
females (Figure 2B). Using qRT-PCR in mouse embryonic 
fibroblasts (MEFs) and liver tissue samples, we have 
demonstrated that Usp54KF/KF mice showed a reduced, but 
not abolished, expression of Usp54, compared to wild-
type animals (Figure 2C). These results suggested that 
Usp54KF/KF mice presented a hypomorphic phenotype. 
We next crossed these animals with mice expressing Cre 
recombinase to generate the KO mice (Usp54∆/∆) through 
the elimination of Usp54 exons 4 to 6. These animals 
were viable and fertile with no obvious abnormalities, 
demonstrating that Usp54 is dispensable for embryonic 
and adult mice development. In the course of phenotypic 
characterization of Usp54KF/KF mice, we found a slight 
increase in body weight in female mice as compared with 
their wild-type littermates kept on standard chow (Figure 
2D). Interestingly, differences in body weight augmented 
when both Usp54-deficient and wild-type female animals 
were fed a high fat diet (Figure 2E and 2F). Accordingly, 
Usp54KF/KF female mice kept on high-fat diet showed a 
significantly larger increase in gonadal and subscapular 
weight fat pads, compared to wild-type animals (Figure 
2G). Thus, histological analysis of white adipose tissue 
from both gonadal and subcutaneous fat deposits revealed 
that Usp54KF/KF mice showed higher adipocyte area than 
Usp54+/+ mice (Figure 2H and 2I). In agreement with these 
data, subcutaneous fat deposits were significantly thicker 
in Usp54KF/KF female mice (Figure 2I and 2J). Collectively, 
Figure 2: Usp54 is dispensable for embryonic development and adult mice lifespan. A., B. Kaplan-Meier survival curves for 
wild-type and Usp54-deficient males (A) and females (B). C. TaqMan-based qRT-PCR analysis of Usp54 in MEFs and liver tissues from 
Usp54+/+ and Usp54KF/KF mice. Data are represented as relative quantification, RQ ± SEM, two-tailed Student’s t-test (**, P < 0.01). D. Body 
weight curves of Usp54+/+ and Usp54KF/KF female mice kept on standard diet. E. Body weight curves of Usp54+/+ and Usp54KF/KF female mice 
kept on high-fat diet and a representative image of females of each genotype at the end of the experiment. F. Total weight gain in the same 
animals. G. Percentage of gonadal and subscapular fat mass with respect to total body weight of the same animals. H. Mean adipocyte area 
in gonadal and skin fat. I. Representative histological images. Scale bar: 20 μm (gonadal fat) and 200 μm (skin fat). J. Average thickness 
of the subcutaneous fat deposits for each genotype. Statistical significance was assessed by a non-parametric Mann Whitney-Wilcoxon test 
(*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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these results demonstrate that Usp54-deficiency is 
compatible with normal mouse development and life, 
although in female animals it leads to an increase in body 
weight due to fat accumulation.
USP54 promotes cancer invasion in chemically-
induced colorectal carcinomas
To investigate USP54 role in colorectal cancer 
development in vivo, we induced colon carcinomas in 
Usp54+/+ and Usp54KF/KF mice, using azoxymethane 
(AOM) and dextran sulfate sodium (DSS) (Figure 3A). All 
wild-type animals, but only 75% of Usp54-deficient mice, 
developed adenocarcinomas (Figure 3B). Considering 
all colorectal carcinomas, the proportion of infiltrating 
adenocarcinomas was lower in Usp54KF/KF mice, compared 
to wild-type animals (Figure 3C). Moreover, the number 
of infiltrating tumors per mouse was significantly 
decreased in Usp54-deficient animals, compared to control 
mice (Figure 3D). Additionally, we measured shortening 
of colon as a marker of inflammation and found that colon 
samples from wild-type mice where shorter than those 
from Usp54-deficient animals (Figure 3E), revealing a 
less severe colitis in the absence of this deubiquitinase. 
These data indicate that USP54 deficiency impedes the 
development of colorectal carcinoma. 
To further clarify the relevance of USP54 in colon 
cancer, we analyzed the expression of this DUB in 
transcriptional data from colorectal adenomas and normal 
mucosa [16] (GEO accession GDS2947). We found a 
significant increase in USP54 expression in adenomas 
compared to matched normal mucosa (Figure 3F). 
Moreover, analysis of reported data on survival of patients 
with intestinal cancer showed a positive correlation 
between high USP54 expression and lower survival 
(Figure 3G). Collectively, these data, together with the 
above finding that USP54 is overexpressed in ISCs, 
support a pro-tumorigenic effect of USP54 in colorectal 
carcinoma. 
USP54 is necessary for metastasis of melanoma 
cells
To further evaluate the role of USP54 in cancer 
progression, we analyzed in vivo the effect of Usp54 
knockdown on the formation of experimental lung 
metastasis by B16F10 murine melanoma cells. For this 
purpose, we transduced B16F10 cells with two different 
Figure 3: USP54 deficiency prevents azoxymethane-induced infiltrating colon tumors. A. Schematic representation of 
azoxymethane-induced colon tumor protocol. B. Percentage of animals with the indicated histological alterations. L-Dys, light dysplasia; 
S-Dys, severe dysplasia; Adeno, adenocarcinomas; Inf. Adeno., infiltrating adenocarcinomas. C. Percentage of infiltrating and mucosal 
tumors within all carcinomas of each genotype and representative histological images. Scale bar: 500 μm. D. Average number of 
adenocarcinomas per mouse. E. Length of the colon at the end of the experiment. F. Analysis of USP54 expression from 32 colorectal 
cancer patient samples, comprising pairs of tumor and matched normal mucosa (GEO accession GDS2947). G. Kaplan-Meier survival plot 
for 269 patients with intestinal cancer grouped as a function of quantile expressions of USP54. Statistical significance was assessed by a 
non-parametric Mann Whitney-Wilcoxon test (*, P < 0.05; **, P < 0.01).
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Usp54-specific shRNAs (shUSP54.913 and shUSP54.263) 
or the empty vector (pLKO.1) and we verified the 
downregulation of Usp54 expression by qRT-PCR (Figure 
4A). Then, we injected 25,000 cells through the jugular 
vein of 8-week-old C57BL/6N mice. After 21 days, the 
animals were sacrificed and their lungs were collected 
for histological analysis. Downregulation of Usp54 
decreased the number of metastases with more than 200 
µm of diameter compared to pLKO.1-transduced control 
cells (Figure 4B and 4C). Interestingly, the inspection 
of publicly available cancer genome databases revealed 
frequent mutations in USP54, especially in melanoma 
and in pancreatic and endometrial carcinomas (http://
cbioportal.org). It is also noteworthy the amplification 
of this gene in neuroendocrine prostate cancer and its 
deletion in malignant peripheral nerve sheath tumor 
(Figure 5). Collectively, these results support the 
essentiality of USP54 for lung metastasis formation in 
vivo, corroborating its oncogenic function in metastatic 
melanoma progression. 
DISCUSSION
The cancer stem cell (CSC) hypothesis proposes 
that tumors arise and are driven by a subset of cancer 
cells that retain stem cell properties [17, 18]. Over the 
last decades, several studies have addressed the role of 
DUBs in stem cell maintenance [19, 20]. In this context, 
we have analyzed the expression profile of several USPs 
in colorectal cancer stem cells, and we have found that 
USP54 is consistently upregulated. Accordingly, we 
have shown that downregulation of USP54 significantly 
decreases the tumorigenicity of colon cancer cells. 
In this work, we have also generated an Usp54-
deficient mouse model and we have shown that these 
animals are viable and fertile, demonstrating that Usp54 is 
dispensable for normal mouse development and survival. 
Interestingly, we have described the presence of metabolic 
alterations in Usp54KF/KF female mice characterized 
by an increase in body weight due to fat accumulation. 
By performing carcinogenesis protocols, we have 
demonstrated the oncogenic relevance of USP54 in colon 
cancer by finding that Usp54 deficiency protects against 
Figure 4: USP54 deficiency inhibits lung metastasis formation. A. TaqMan-based qRT-PCR analysis of Usp54 expression 
in B16F10 cells transduced with the indicated Usp54-specific shRNA or the empty lentiviral vector (pLKO.1) as a control. Data are 
represented as relative quantification, RQ ± SEM, two-tailed Student’s t-test (***, P < 0.001). B. Number of metastases bigger than 200 
µm in diameter. Statistical significance was assessed using a non-parametric Mann Whitney-Wilcoxon test (*, P < 0.05; ***, P < 0.001). 
C. Representative images of lungs and histological analysis for each condition. Scale bar: 200 μm.
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chemically-induced colorectal carcinoma. In agreement 
with these results, USP54 is overexpressed in human colon 
cancer and those cases with higher expression levels of this 
gene present a poorer prognosis. These results, together 
with the finding that USP54 is upregulated in colon CSCs, 
support the oncogenic function of this deubiquitinase in 
colorectal cancer progression. Additionally, we have found 
that Usp54 downregulation impairs experimental lung 
metastasis formation by melanoma cells, corroborating 
the pro-tumoral effect of USP54 also in this pathology. 
In agreement with these results, mutations in USP54 
have been recently described in human leukemia, 
confirming the importance of this deubiquitinase in both 
hematological malignancies and solid tumors [14].
In summary, we have demonstrated that USP54 is 
overexpressed in colon CSCs and promotes both colon 
carcinoma and melanoma progression. In this regard, 
future studies will be required to clarify the molecular 
mechanisms underlying the pro-tumoral effect of USP54 
in cancer progression demonstrated in this work and to 
explore the translatability of these findings into clinical 
benefits for cancer patients. 
MATERIALS AND METHODS
Generation of Usp54KF/KF mice and genotyping
Usp54-mutant embryonic stem cells (ESCs) from 
the C57BL/6N mouse strain were purchased from KOMP. 
Two different clones of targeted ESCs (EPD0833_2_
B10 and EPD0833_2_D09) were microinjected into 
C57BL/6N mouse blastocysts to produce chimeric mice 
that were then subsequently crossed with wild-type 
C57BL/6N mice to generate Usp54-heterozygous mice. 
The Usp54-KF allele was identified by PCR on genomic 
DNA from tail samples under the following conditions: 
denaturation at 94 °C for 30 s, annealing at 60 °C for 30 
s, and extension at 72 °C for 30 s, 30 cycles. We used 
the following primers for genotyping: wild-type-specific 
forward 5’-ccataatcccagcacctaagag-3’, mutation-specific 
forward 5’-caagtgtggagggtggtgt-3’, and common reverse 
5’-ctggaagtaaacagaccggagt-3’.
Animal care
All animal procedures were approved by 
the Committee for Animal Experimentation of the 
Universidad de Oviedo and performed in accordance with 
the guidelines of the Committee. Cre transgenic mice 
were obtained from Jackson Laboratory (No 006054). For 
diet-induced obesity, 4-week-old Usp54-deficient mice 
and their wild-type littermates were fed a high-fat diet 
containing 60% fat for 24 weeks (Research Diet, D12492). 
Mice were weighted once a week for all the duration of 
the experiment. For blood glucose measurements, blood 
from the tail vein was analyzed by using the Accu-Chek 
glucometer (Roche Diagnostics).
Colon carcinogenesis protocol
For colon carcinogenesis induction, 9-week-old 
female mice were injected intraperitoneally with 12.5 mg/
kg AOM (azoxymethane; Sigma-Aldrich, St. Louis, MO, 
USA). After 5 days, DSS (dextran sulfate sodium; MP 
Biomedicals) at 1.5% was administered in the drinking 
water for 5 consecutive days. Next, mice received reverse 
osmosis water for 16 days and two more DSS cycles at 
Figure 5: USP54 alterations in human cancer. Summary of USP54 genetic alterations found in human cancer. ACC, Adrenocortical 
Carcinoma; Adeno, Adenocarcinoma; CCLE, Cancer Cell Line Encyclopedia; chRCC, Kidney Chromophobe; CS, Carcinosarcoma; 
DESM, Desmoplastic Melanoma; MPNST, Malignant Peripheral Nerve Sheath Tumor; NEPC, Neuroendocrine Prostate Cancer; PAAC, 
Acinar Cell Carcinoma of the Pancreas; SC, Small Cell; Sq and Squ, Squamous Cell Carcinoma; ucs, Uterine Carcinosarcoma. Data were 
obtained from cBioportal (http://cbioportal.org).
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1.5% were administered, with another interval of 16 days 
on water between them. 10 days after the last DSS cycle, 
mice were euthanized and colons were extracted, flushed 
with phosphate-buffered saline (PBS) and measured in 
length. The colons were fixed in 4% paraformaldehyde 
(PFA) and transversal sections were hematoxylin and 
eosin (H&E) stained. The tumors were counted and 
their histological features, as well as the grade of the 
inflammatory lesions, were analyzed for each mouse.
Cell culture
Cancer cell lines HEK 293T and HCT116 were 
purchased from the American Type Culture Collection. 
Cells were routinely maintained in Dulbecco’s modified 
Eagle’s medium containing 10% fetal bovine serum, 
100 U/ml penicillin, and 100 μg/ml streptomycin (Life 
Technologies). 
shRNA lentiviral infection
The two best shRNAs of both human and murine 
sets of 5 USP54-specific shRNA vectors, and empty 
vector, pLKO.1 (Open Biosystems, Thermo Scientific) 
were packaged in HEK 293T cells using a VSVG-
based package system. After 24 h, viral supernatant was 
collected and added in a 1:3 dilution to previously seeded 
HCT116 or B16F10-luc2 cells, supplemented with 5 mg/
ml of polybrene (Millipore). Stably transduced cells were 
selected with puromycin at a final concentration of 1 µg/
ml. 
Real-time quantitative PCR (qRT-PCR) analysis
2 µg of total RNA from cells, isolated with RNeasy 
kit (Qiagen), was used to synthesize cDNA using 
the ThermoScript™ Reverse Transcriptase kit (Life 
Technologies). Then, qRT-PCR was performed using 
TaqMan® gene expression assay for murine samples 
(Usp54, Mm00513373_m1) or Power SYBR® Green PCR 
Master Mix for human cells (Life Technologies), using 
an Applied Biosystems 7300HT Real-Time PCR System. 
Relative expression was calculated as RQ=2-ΔΔCt. 
Soft agar colony formation
To determine anchorage-independent growth of 
HCT116 cells, 1,000 cells were seeded per well into 96-
well plates and maintained during 8 days at 37 °C and 
5% CO2. Then, a CytoSelect™ 96-Well In Vitro Tumor 
Sensitivity Assay kit (Cell Biolabs) was used, following 
the manufacturer’s instructions. 
Cell-proliferation assay
To quantify cell proliferation, we seeded 5,000 
HCT116 cells transduced with either control (pLKO.1) 
or USP54-specific shRNAs per well (n = 6) into 96-
well plates. Next, a Cell Titer 96 Non-Radioactive Cell 
Proliferation kit (Promega Corp.) was used following the 
manufacturer’s instructions. 
Mouse xenograft model
Xenograft experiments were performed as 
previously described [21]. Briefly, 2 million control 
or USP54-silenced HCT116 cells were injected 
subcutaneously in both flanks of eight-week-old athymic 
Nude-Foxn1nu/nu mice (Charles River). Tumor size was 
measured twice per week using a caliber and mice were 
sacrificed 32 days post-injection.
Lung metastasis protocol
For lung metastasis experimental model, 25,000 
control or Usp54-silenced B16F10-luc2 tumor cells 
were injected through the jugular vein of previously 
anesthetized mice. After 3 weeks, mice were sacrificed and 
lungs were collected, fixed in 4% PFA in PBS and stored 
in 70% ethanol until analysis. Then, fixed tissues were 
embedded in paraffin by standard procedures and blocks 
were sectioned and stained with H&E. Serial sections of 
the lung (at least 10 sections spaced 100 µm) were stained 
with H&E, and metastatic foci were counted. Metastases 
were classified as small (<200 µm diameter), medium 
(between 200 and 400 µm diameter), and large (>400 µm 
diameter). 
Survival analysis
KM-plotter [22] (www.kmplot.com) was used 
to assess the effect of USP54 expression on survival of 
intestinal cancer patients. 
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